糖皮质激素致乙型肝炎病毒再激活——皮肤科亟须重视的问题

doi:10.3760/cma.j.issn.0412-4030.2019.02.016

摘要/Abstract

摘要： 【摘要】乙型肝炎（乙肝）在我国发病率较高，皮肤科医师在诊治过程中常遇到合并乙型肝炎病毒（HBV）感染的皮肤病患者。随着皮肤科系统应用糖皮质激素越来越广泛，HBV再激活已经成为治疗过程中需要不断面临的问题。应重视HBV再激活的危险因素：HBV DNA复制、乙肝表面抗原阳性和乙肝核心抗体阳性；根据HBV血清学标志物掌握糖皮质激素致HBV再激活的危险分层，并及时采取治疗措施预防HBV再激活，可以最大程度避免糖皮质激素治疗过程中HBV再激活导致的肝功能损伤。

关键词: 糖皮质激素类 , 乙型肝炎病毒, 乙型肝炎, 病毒激活

Abstract: 【Abstract】 There is a high incidence of hepatitis B virus （HBV） infection in China, and dermatologists often encounter patients with skin diseases complicated by HBV infection in clinic. With the widespread use of systemic glucocorticoids in dermatology, HBV reactivation has become a constant problem to face in the treatment process. Attention should be given to risk factors of HBV reactivation, including HBV DNA replication, positive hepatitis B surface antigens （HBsAg） and positive hepatitis B core antibodies （HBcAb）. According to HBV serological markers, risk stratification of HBV reactivation induced by glucocorticoids needs to be grasped, and treatment measures should be taken timely to prevent HBV reactivation. In this way, liver function impairment induced by HBV reactivation during the course of glucocorticoid therapy may be avoided to the greatest extent, which is of great benefit to clinical work.

Key words: Glucocorticoids, Hepatitis B virus, Hepatitis B, Virus activation

宋秀祖华优. 糖皮质激素致乙型肝炎病毒再激活——皮肤科亟须重视的问题[J]. 中华皮肤科杂志, 2019, 52(2): 124-127.

Song Xiuzu, Hua You. Hepatitis B virus reactivation induced by glucocorticoids: an important issue requiring urgent attention in dermatology[J]. Chinese Journal of Dermatology, 2019, 52(2): 124-127.

参考文献 24

［1］	Salpini R, Colagrossi L, Bellocchi MC, et al. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression［J］. Hepatology, 2015,61（3）:823⁃833. doi: 10.1002/hep.27604.
［2］	Pattullo V. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression ⁃ prevention is better than cure［J］. World J Hepatol, 2015,7（7）:954⁃967. doi: 10.4254/wjh.v7.i7.954.
［3］	Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy［J］. Nat Rev Gastroenterol Hepatol, 2014,11（4）:209⁃219. doi: 10.1038/nrgastro.2013.216.
［4］	Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus （HBV） reactivation in cancer patients undergoing cytotoxic chemotherapy［J］. Br J Cancer, 2004,90（7）:1306⁃1311. doi: 10.1038/sj.bjc.6601699.
［5］	Ferraro D, Pizzillo P, Di MV, et al. Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?［J］. Liver Int, 2009,29（8）:1171⁃1177. doi: 10.1111/j.1478⁃3231.2009.02071.x.
［6］	Pérez⁃Alvarez R, Díaz⁃Lagares C, García⁃Hernández F, et al. Hepatitis B virus （HBV） reactivation in patients receiving tumor necrosis factor （TNF）⁃targeted therapy: analysis of 257 cases［J］. Medicine （Baltimore）, 2011,90（6）:359⁃371. doi: 10. 1097/MD.0b013e3182380a76.
［7］	An J, Shim JH, Kim SO, et al. Comprehensive outcomes of on⁃ and off⁃antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: a competing risks analysis［J］. J Med Virol, 2016,88（9）:1576⁃1586. doi: 10.1002/jmv.24512.
［8］	Mei B, Chen Y, Liu W, et al. mRNA of glucocorticoid receptor and serological and virological markers of chronic hepatitis B［J］. Mol Med Rep, 2015,11（3）:2215⁃2220. doi: 10. 3892/mmr.2014.2931.
［9］	喻一奇, 宣丹旦, 王佳俐, 等. 风湿性疾病合并乙型肝炎病毒感染12例不同免疫抑制治疗后病毒再激活的随访观察［J］. 中华风湿病学杂志, 2015,19（4）:261⁃266. doi: 10.3760/cma.j.issn.1007⁃7480.2015.04.011.
［10］	Kim TW, Kim MN, Kwon JW, et al. Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids［J］. Respirology, 2010,15（7）:1092⁃1097. doi: 10.1111/j.1440⁃1843.2010.01798.x.
［11］	Cheng AL, Hsiung CA, Su IJ, et al. Steroid⁃free chemotherapy decreases risk of hepatitis B virus （HBV） reactivation in HBV⁃carriers with lymphoma［J］. Hepatology, 2003,37（6）:1320⁃1328. doi: 10.1053/jhep.2003.50220.
［12］	Li X, Tian J, Wu J, et al. A comparison of a standard⁃dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study［J］. Clin Ther, 2009,31（4）:741⁃750. doi: 10.1016/j.clinthera.2009.04.011.
［13］	Law MF, Ho R, Cheung CK, et al. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy［J］. World J Gastroenterol, 2016,22（28）:6484⁃6500. doi: 10.3748/wjg.v22.i28.6484.
［14］	Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy［J］. Gastroenterology, 2015,148（1）:215⁃219. doi: 10.1053/j.gastro.2014.10.039.
［15］	Karadag Ö, Kaşifoglu T, Özer B, et al. Viral hepatitis screening guideline before biological drug use in rheumatic patients［J］. Eur J Rheumatol, 2016,3（1）:25⁃28. doi: 10.5152/eurjrheum.2015. 150072.
［16］	Perrillo RP, Gish R, Falck⁃Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosu⁃ppressive drug therapy［J］. Gastroenterology, 2015,148（1）:221⁃244.e3. doi: 10.1053/j.gastro.2014.10.038.
［17］	Ohishi W, Chayama K. Prevention of hepatitis B virus reacti⁃vation in immunosuppressive therapy or chemotherapy［J］. Clin Exp Nephrol, 2011,15（5）:634⁃640. doi: 10.1007/s10157⁃011⁃0464⁃7.
［18］	Yoo JJ, Cho EJ, Cho YY, et al. Efficacy of antiviral prophylaxis in HBsAg⁃negative, anti⁃HBc positive patients undergoing hematopoietic stem cell transplantation［J］. Liver Int, 2015,35（12）:2530⁃2536. doi: 10.1111/liv.12882.
［19］	Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab⁃containing chemotherapy for lymphoma: a prospective study［J］. J Clin Oncol, 2014,32（33）:3736⁃3743. doi: 10.1200/JCO.2014.56.7081.
［20］	Buti M, Manzano ML, Morillas RM, et al. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti⁃HBc⁃positive patients with rituximab⁃based regimens to treat hematologic malignancies: The Preblin study［J］. PLoS One, 2017,12（9）:e0184550. doi: 10.1371/journal.pone.0184550.
［21］	McMahon BJ. Implementing evidenced⁃based practice guidelines for the management of chronic hepatitis B virus infection［J］. Am J Med, 2008,121（12 Suppl）:S45⁃S52. doi: 10.1016/j.amjmed. 2008.09.028.
［22］	European Association for the Study of the Liver. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection［J］. J Hepatol, 2017,67（2）:370⁃398. doi: 10.1016/ j.jhep.2017.03.021.
［23］	张浩晔, 刘振国, 张震, 等. 核苷类似物防治乙型肝炎表面抗原阳性的肿瘤患者化疗后乙型肝炎病毒再激活的临床分析［J］. 中华肿瘤杂志, 2010,32（6）:459⁃462. doi: 10.3760/cma.j.issn.0253⁃3766.2010.06.015.
［24］	孔媛媛, 尤红, 贾继东, 等. 世界卫生组织《慢性乙型肝炎病毒感染预防、关怀和治疗指南》制定方法学和核心建议点评［J］. 中华肝脏病杂志, 2015,23（7）:485⁃487. doi: 10.3760/cma.j.issn.1007⁃3418.2015.07.003.

[1]	张静薛峤范文葛魏梅王玲赵军丁浩陶晓瑜. 联用糖皮质激素治疗老年头面部带状疱疹的疗效[J]. 中华皮肤科杂志, 2018, 51(9): 670-672.
[2]	肖媛媛徐子刚徐哲向欣刘盈马琳杨舟. 长春新碱联合糖皮质激素治疗11例婴儿期Kasabach-Merritt综合征[J]. 中华皮肤科杂志, 2018, 51(8): 601-603.
[3]	鲁静浩刘超凡周行胡东艳辛崇美朱鹭冰李明. 伴手掌疼痛性皮疹的皮肌炎合并致死性急进性间质性肺病四例临床分析[J]. 中华皮肤科杂志, 2018, 51(8): 564-568.
[4]	华优王敏高亚丽耿清伟相文忠宋秀祖. 糖皮质激素诱发类固醇糖尿病38例临床分析[J]. 中华皮肤科杂志, 2018, 51(4): 269-273.
[5]	康玉英何肖刘勇常慧玲邓起杨元文徐凯郭荣王丽. 急性荨麻疹住院患者185例回顾分析[J]. 中华皮肤科杂志, 2018, 51(3): 224-227.
[6]	路雪艳庞艳华黄二顺李邻峰. 糖皮质激素和抗菌药物联合外用治疗湿疹的疗效观察[J]. 中华皮肤科杂志, 2013, 46(1): 40-42.
[7]	刘伦飞王建有劳力民曹越兰郑敏. SLE患者胰岛素抵抗和血清抵抗素水平研究[J]. 中华皮肤科杂志, 2009, 42(9): 593-595.
[8]	谭国珍, 彭辉, 毛越苹, 曾凡钦. 糖皮质激素上调系统性红斑狼疮患者外周血CD4⁺CD25⁺T细胞CD62L的表达[J]. 中华皮肤科杂志, 2007, 40(6): 362-364.
[9]	王娣, 陈喜雪, 朱学骏. 124例大疱性类天疱疮治疗回顾[J]. 中华皮肤科杂志, 2007, 40(1): 7-9.
[10]	游弋, 郝飞, 邓永键. 糖皮质激素对SLE患者CD4⁺, CD8⁺T细胞Caspase-3及TRAIL受体基因表达的影响[J]. 中华皮肤科杂志, 2007, 40(1): 19-21.
[11]	杨雪源, 胡兹嘉, 毕志刚, 顾军, 范卫新, 王塞枫, 于浩, 娄冬华. 糠酸莫米松乳膏治疗湿疹皮炎类皮肤病多中心临床研究[J]. 中华皮肤科杂志, 2005, 38(1): 41-43.
[12]	李捷, 谢红付, 施为, 陈明亮, 陈翔, 杜乾君, 陈服文. 糖皮质激素对SLE患者Th1/Th2类细胞因子mRNA表达及产生的影响[J]. 中华皮肤科杂志, 2004, 37(12): 706-708.
[13]	周平玉, 廖康煌, 徐明, 王侠生. 皮质类固醇对二期显性梅毒外周血T淋巴细胞及其预后的影响[J]. 中华皮肤科杂志, 2001, 34(2): 122-123.
[14]	汪治中, 郑茂荣, 李怀义, 牟贤龙. 银屑病患者淋巴细胞和角朊细胞染色体畸变及银屑病与乙型肝炎病毒的关系[J]. 中华皮肤科杂志, 1997, 30(2): 93-95.